Skip to main content
Alphamab Oncology logo

Alphamab Oncology — Investor Relations & Filings

Ticker · 9966 ISIN · KYG0330A1013 LEI · 254900VOW925DTFGNA02 HKEX Manufacturing
Open in API
Filings indexed 368 across all filing types
Latest filing 2020-01-08 Share Issue/Capital Cha…
Country KY Cayman Islands
Listing HKEX 9966

About Alphamab Oncology

http://www.alphamabonc.com

Alphamab Oncology is an innovative biopharmaceutical company specializing in the research, development, and commercialization of differentiated anti-tumor biotherapeutics. The company is dedicated to addressing unmet clinical needs in oncology by developing effective, safe, and globally competitive cancer therapies. A core unique selling point is its proprietary technology platform for Antibody-Drug Conjugates (ADCs). This platform utilizes site-specific conjugation via Fc glycan, employing a one-enzyme, two-step process to produce ADCs with a highly uniform Drug-to-Antibody Ratio (DAR). This method results in superior serum stability and enhanced bystander killing effect, aiming to widen the therapeutic window and minimize toxic side effects. Key pipeline assets include KN035 and the biparatopic HER2-targeting ADC, JSKN003, which has received Breakthrough Therapy Designation from the FDA.

Recent filings

Filing Released Lang Actions
Next Day Disclosure Return
Share Issue/Capital Change Classification · 95% confidence The document is a Next Day Disclosure Return for a Main Board listed issuer, Alphamab Oncology, reporting changes in issued share capital and share buybacks. It includes detailed information about share issues, repurchases, and confirmations related to compliance with listing rules. The content focuses on capital changes and share transactions rather than financial results, management changes, or regulatory filings. The document length is 8419 characters, indicating it is a substantive disclosure rather than a brief announcement. This matches the definition of a Share Issue/Capital Change filing, which covers announcements regarding new share issues, stock splits, or other capital changes.
2020-01-08 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2019
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 31/12/2019 and is addressed to the Hong Kong Exchanges and Clearing Limited. It details movements in authorized and issued share capital, share options, warrants, convertibles, and other share-related capital changes. The content is focused on share capital changes and securities movements rather than financial performance, management changes, or earnings. It is a regulatory filing reporting monthly share capital movements to the exchange, not a report like an annual or interim report, nor an announcement of voting results or capital raising. The document is comprehensive and contains substantive data on share capital movements, fitting the category of Share Issue/Capital Change (SHA).
2020-01-06 English
FULL EXERCISE OF THE OVER-ALLOTMENT OPTION, STABILIZING ACTIONS AND END OF STABILIZATION PERIOD
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the full exercise of the over-allotment option, stabilizing actions, and the end of the stabilization period related to a global offering of shares by Alphamab Oncology. It discusses share allotment, shareholding structure changes, use of proceeds, and regulatory compliance with the Hong Kong Stock Exchange listing rules. The document is not a financial report, earnings release, or management discussion but rather a formal announcement about capital market activities related to share issuance and stabilization. This fits the definition of a Capital/Financing Update (CAP) as it provides updates on company fundraising and capital structure changes. The document length is over 11,000 characters and contains detailed information, not just a brief notice or report publication announcement.
2020-01-05 English
INSIDE INFORMATION ANNOUNCEMENT - COLLABORATIVE PARTNERSHIP AGREEMENT WITH TRACON AND 3DMED
Regulatory Filings Classification · 95% confidence The document is an announcement by Alphamab Oncology regarding a collaborative partnership agreement with Tracon and 3DMed. It is labeled as an "Inside Information Announcement" and references compliance with the Listing Rules of the Hong Kong Stock Exchange. The content focuses on the terms of the partnership, licensing, and royalty arrangements related to a drug candidate KN035. There are no financial statements, quarterly or annual results, or detailed financial data presented. The document is relatively short (4512 characters) and serves as a regulatory announcement of a material business development rather than a financial report or detailed investor presentation. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Management Discussion. It is not a call transcript, nor a governance or remuneration report. It is a regulatory announcement about a significant business event, thus best classified under Regulatory Filings (RNS).
2019-12-20 English
VOLUNTARY ANNOUNCEMENT - COMPLETION OF CONSTRUCTION OF THE PHASE I MANUFACTURING FACILITIES
Regulatory Filings Classification · 90% confidence The document is a voluntary announcement by Alphamab Oncology regarding the completion of construction of Phase I manufacturing facilities. It provides details about the facilities, their capacity, and the company's business. The document is relatively short (3802 characters) and does not contain financial statements, detailed financial performance, or regulatory filings. It is an update on business progress rather than a formal report or regulatory filing. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is an announcement about a business development, which aligns best with a general Regulatory Filing (RNS) as it does not fit more specific categories like Capital/Financing Update or M&A Activity. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2019-12-18 English
VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN A PHASE II CLINICAL TRIAL OF KN019 FOR RHEUMATOID ARTHRITIS TREATMENT IN CHINA
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Alphamab Oncology regarding the dosing of the first patient in a Phase II clinical trial for a drug candidate. It is an update on business progress and clinical development, not a financial report or regulatory filing. The document is relatively short (3985 characters) and serves as a business update rather than a detailed report or presentation. It does not contain financial data, management changes, voting results, or other specific report content. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other categories.
2019-12-16 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.